Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CBP20 CRISPR/Cas9 KO Plasmid (h): sc-404124
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CBP20 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CBP20 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CBP20 Antibody (B-1): sc-137123
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CBP20 CRISPR/Cas9 KO Plasmid (h) | sc-404124 | 20 µg | $397.00 |
Overview
NCBP2 encodes CBP20, the small subunit of the nuclear cap-binding complex that recognizes the 7-methylguanosine cap on nascent RNA polymerase II transcripts. By coupling cap recognition to RNA processing, CBP20 supports pre-mRNA splicing, 3′ end formation, nuclear export, and RNA surveillance pathways including nonsense-mediated mRNA decay. Through these functions, NCBP2 helps coordinate gene expression programs and transcriptome integrity during cell growth and stress responses. Dysregulation of cap-dependent RNA metabolism and mRNA quality control has been linked to oncogenic transcriptional states and neurodevelopmental phenotypes, making NCBP2 a useful node for studying disease-associated RNA processing mechanisms.
CBP20 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NCBP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NCBP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NCBP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CBP20 protein expression.
This CRISPR knockout system enables efficient generation of NCBP2-deficient cell models for investigation of CBP20 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting NCBP2 exon(s) critical for CBP20 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple NCBP2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CBP20 CRISPR/Cas9 KO Plasmid (h) and CBP20 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NCBP2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CBP20 HDR Plasmid (h) and CBP20 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NCBP2 homology arms to support homology-directed repair at defined NCBP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.